Shelby Giza

Shelby Giza has a diverse work experience in the scientific and biomedical field. Shelby is currently the Director of Scientific Business Strategy at Space Tango, where they develop strategies for research and development in low Earth orbit using their knowledge of the terrestrial biomedical market. Shelby also strengthens business relationships with stakeholders and manages a team of scientists.

Before their current role, Shelby worked as a Principal Scientist at Space Tango, where they led a continuous improvement process and developed training programs for project team members to ensure the success of microbe-free flight payloads.

Prior to their work at Space Tango, Shelby held positions at the University of Florida College of Pharmacy, where they contributed to the Tissue Chips in Space Initiative by developing 3D human muscle tissue chips.

Shelby also has experience as a PK/PD Clinical Assay Scientist at Alopexx Enterprises, LLC and as a Scientist at Novartis Institutes for BioMedical Research (NIBR), where they contributed to the research and development of therapeutic drugs.

Earlier in their career, Shelby worked at Boston Scientific, RenaMed Biologics, Inc., and Dana-Farber Cancer Institute, where they gained experience in cell biology, manufacturing, and biomedical research.

Overall, Shelby Giza has demonstrated expertise in various aspects of scientific research, development, and strategy in the biomedical field.

Shelby Giza holds a Bachelor of Science (B.S.) degree in Chemistry from the University of Massachusetts Dartmouth. In addition to their degree, they have obtained certifications in Good Laboratory Practice (GLP) from the CITI Program, A Division of BRANY, in January 2019, and GCP for Clinical Trials with Investigational Drugs and Medical Devices (U.S. FDA Focus) also from the CITI Program, A Division of BRANY, in December 2018.